{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:04:13Z","timestamp":1716336253542},"reference-count":81,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer Manage."],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.2217\/lmt.13.62","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T17:38:35Z","timestamp":1385660315000},"page":"517-525","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy Treatments for Small-Cell Lung Cancer: Past, Present and Future"],"prefix":"10.1080","volume":"2","author":[{"given":"Matthew","family":"Whitehurst","sequence":"first","affiliation":[{"name":"Hematology Oncology, Moffitt Cancer Center - Graduate Medical Education Office,\r12902 Magnolia Drive,\rTampa,\rFL\r33612,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Chiappori","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Program, Moffitt Cancer Center,\rOffice Building Level 1, 12902 Magnolia Drive,\rTampa,\rFL\r33612,\rUSA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,11,28]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.12.006"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212033272302"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.6.890"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0011"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.282"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.10.2022"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.395"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.117"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2114"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2300"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.3423"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp200"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318155a439"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2010.n.028"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181cee36e"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.12.002"},{"key":"e_1_3_2_3_18_1","article-title":"A Phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer.","volume":"29","author":"Venepalli NK","year":"2012","unstructured":"Venepalli NK , HutchisonAS, CarboneDPet al. A Phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer. J. Clin. Oncol. 29, Abstract 7094 (2012).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728210903206983"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481302000105"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1434::AID-CNCR3>3.0.CO;2-C"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410370708"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds260"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1156"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50018"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.10.6074-6083.2001"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.2.4027"},{"issue":"4","key":"e_1_3_2_3_30_1","first-page":"679","article-title":"Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.","volume":"2","author":"McCaffery M","year":"1996","unstructured":"McCaffery M , YaoTJ, WilliamsL, LivingstonPO, HoughtonAN, ChapmanPB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.Clin. Cancer Res.2(4), 679\u2013686 (1996).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"e_1_3_2_3_31_1","first-page":"1319","article-title":"Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin.","volume":"5","author":"Grant SC","year":"1999","unstructured":"Grant SC , KrisMG, HoughtonAN, ChapmanPB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin.Clin. Cancer Res.5(6), 1319\u20131323 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.186"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.2.3574"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1083-6"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02202.x"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.484801"},{"issue":"6","key":"e_1_3_2_3_37_1","first-page":"1281","article-title":"Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.","volume":"5","author":"Chikamatsu K","year":"1999","unstructured":"Chikamatsu K , NakanoK, StorkusWJet al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res. 5(6), 1281\u20131288 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.376"},{"issue":"6","key":"e_1_3_2_3_39_1","first-page":"2138","article-title":"Gain-of-function mutations in the tumor suppressor gene p53.","volume":"6","author":"van Oijen MG","year":"2000","unstructured":"van Oijen MG , SlootwegPJ. Gain-of-function mutations in the tumor suppressor gene p53.Clin. Cancer Res.6(6), 2138\u20132145 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2013"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.08.013"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67250"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1396-8"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0523-4"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1889-0"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.3069"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2432664"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/107999002753536130"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90526-8"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1089\/107999099314180"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(98)00092-0"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200002000-00006"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S43184"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.041"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.045"},{"issue":"4","key":"e_1_3_2_3_56_1","first-page":"1011","article-title":"Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a Phase III randomized multicentric trial.","volume":"39","author":"Ridolfi L","year":"2011","unstructured":"Ridolfi L , BertettoO, Santoet al. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a Phase III randomized multicentric trial. Int. J. Oncol. 39(4), 1011\u20131017 (2011).","journal-title":"Int. J. Oncol."},{"issue":"6","key":"e_1_3_2_3_57_1","first-page":"1275","article-title":"Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a Phase II study.","volume":"20","author":"Recchia F","year":"2002","unstructured":"Recchia F , De FilippisS,RosselliM,SaggioG,FumagalliL,ReaS. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a Phase II study.Int. J. Oncol.20(6), 1275\u20131282 (2002).","journal-title":"Int. J. Oncol."},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.3074"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.015"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2010.0865"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds213"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.12.009"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057"},{"key":"e_1_3_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9515-2"},{"key":"e_1_3_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.005"},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.3000"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.3061"},{"key":"e_1_3_2_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.18084"},{"issue":"11","key":"e_1_3_2_3_74_1","first-page":"1235","article-title":"Significance of MOC-31 and CD56 detection in human lung carcinoma tissues.","volume":"21","author":"Huang YG","year":"2002","unstructured":"Huang YG , XuYY, ZhengZH. Significance of MOC-31 and CD56 detection in human lung carcinoma tissues.Ai Zheng21(11), 1235\u20131237 (2002).","journal-title":"Ai Zheng"},{"key":"e_1_3_2_3_75_1","doi-asserted-by":"publisher","DOI":"10.1159\/000346394"},{"key":"e_1_3_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1706"},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.266"},{"key":"e_1_3_2_4_2_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. www.seer.cancer.gov (Accessed 24July2013)"},{"key":"e_1_3_2_4_3_1","unstructured":"To immunize patients with extensive stage SCLC combined with chemo with or without all trans retinoic acid (2013). www.clinicaltrials.gov\/ct2\/results?term=NCT00617409 (Accessed 24July2013)"},{"key":"e_1_3_2_4_4_1","unstructured":"Trial in extensive-disease small cell lung cancer (ED-SCLC) subjects comparing ipilimumab PLUS etoposide and platinum therapy to etoposide and platinum therapy alone (2013). www.clinicaltrials.gov\/ct2\/results?term=nct01450761 (Accessed 24July2013)"},{"key":"e_1_3_2_4_5_1","unstructured":"The addition of ipilimumab to carboplatin and etoposide chemotherapy for extensive stage small cell lung cancer (ICE) (2011). www.clinicaltrials.gov\/ct2\/results?term=nct01331525 (Accessed 24July2013)"}],"container-title":["Lung Cancer Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/lmt.13.62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T19:08:43Z","timestamp":1716318523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/lmt.13.62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,28]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.2217\/lmt.13.62"],"URL":"https:\/\/doi.org\/10.2217\/lmt.13.62","relation":{},"ISSN":["1758-1966","1758-1974"],"issn-type":[{"value":"1758-1966","type":"print"},{"value":"1758-1974","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,28]]}}}